BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 31, 2013
View Archived Issues
RespiVert presents results for the novel PI3K-gamma/delta inhibitor
Read More
Researchers identify novel plasma miRNA biomarkers for the diagnosis and prognosis of AAAs
Read More
Pfizer designs approach to develop potent brain-specific PET tracers
Read More
Novel RNAi therapeutics presented by Gradalis
Read More
Calimmune presents preclinical results for its anti-HIV lentiviral vector gene therapy
Read More
Targacept reports commencement of phase IIb TC-5214 study
Read More
Atopix receives U.K. Biomedical Catalyst grant
Read More
Novel PARP-1 inhibitors created at IMPACT Therapeutics
Read More
GlaxoSmithKline acquires vaccine developer Okairos
Read More
New IRAK-4 inhibitors designed by Merck & Co.
Read More
NICE issues final draft guidance recommending selective dapagliflozin use
Read More
AbbVie introduces high-dose Creon capsules in U.S.
Read More
Beijing Drug Administration accepts Sinovac's filing for EV71 vaccine candidate
Read More
Array BioPharma patents novel GPR119 receptor agonists
Read More
Encouraging topline results seen in phase II ofatumumab study
Read More
Chinese researchers report new cancer therapeutics
Read More
Idenix begins phase II study of all-oral combination of simeprevir and samatasvir for HCV
Read More
Researchers at Eli Lilly disclose novel retinoid RAR-gamma receptor antagonists
Read More
Novan reports promising findings from phase I study of acne treatment
Read More
Phase II trial to evaluate Immunovaccine's DPX-Survivac in glioblastoma
Read More
SBIR grant awarded to Orphagen for the development of novel small molecules
Read More
NEOMED and AstraZeneca expand strategic partnership
Read More
BioMarin's applications for Vimizim accepted by both FDA and EMA
Read More
FDA lifts clinical hold on phase II study of PharmAthene's anthrax vaccine
Read More
Endo Pharmaceuticals receives complete response letter from FDA regarding Aveed NDA
Read More